News

Stephenson Harwood advises Apposite Capital on Emblation investment

Law firm Stephenson Harwood LLP has advised healthcare investor Apposite Capital on its investment in medical device company, Emblation.

Stephenson Harwood advises e-therapeutics plc on £22.5 million fundraise

Law firm Stephenson Harwood LLP has advised e-therapeutics plc on a fundraise of £22.5 million.

Stephenson Harwood advises GE Healthcare on transformative Zionexa acquisition

Law firm Stephenson Harwood LLP has advised GE Healthcare on the acquisition of Zionexa. GE Healthcare is a medical technology, pharmaceutical diagnostics, and digital solutions company; Zionexa…

Partner Alexandra Pygall joins Babraham Institute Board

Stephenson Harwood partner Alexandra Pygall has been appointed to The Babraham Institute’s Board of Trustees.

Stephenson Harwood advises Acacia Pharma on €27 million fundraise

Law firm Stephenson Harwood LLP has advised Acacia Pharma Group plc on its successful €27 million fundraise, through the placing of 10 million new ordinary shares with institutional investors in…

Stephenson Harwood advises Schroder UK Public Private Trust on £49 million asset sale

Law firm Stephenson Harwood LLP has acted for Schroder UK Public Private Trust plc (SUPP) on an agreement for the £49 million sale of seven portfolio assets to Rosetta Capital VI, LP, an…

Stephenson Harwood advises Oxford Biomedica on gene therapy collaboration

Law firm Stephenson Harwood LLP has advised gene and cell therapy company Oxford Biomedica on its collaboration with biopharmaceutical company PhoreMost, to develop next-generation CAR-T cell…

Stephenson Harwood advises capiton on KD Pharma single-asset secondary

Law firm Stephenson Harwood LLP has advised private equity firm capiton on a general partner-led single asset secondary transaction relating to the KD Pharma Group.

Stephenson Harwood advises Oxford Biomedica on COVID-19 vaccine with AstraZeneca

Law firm Stephenson Harwood LLP has advised Oxford Biomedica plc (Oxford Biomedica), a gene and cell therapy company, on a Clinical and Commercial Supply Agreement with AstraZeneca UK Ltd (…